- Conditions
- Healthy
- Interventions
- Oxycodone
- Drug
- Lead sponsor
- Pain Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 387
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy
- Interventions
- AZD5847, Placebo to AZD5847
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non Alcoholic Steatohepatitis, NAFLD, NASH
- Interventions
- Hyperpolarized (HP) 13C, Hyperpolarized 13C-Urea, Magnetic Resonance Imaging, Saline Flush
- Drug · Procedure
- Lead sponsor
- Michael Ohliger, MD PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Prediabetic State
- Interventions
- Rimonabant, Placebo (for Rimonabant)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 2,420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Shigellosis
- Interventions
- Shigella sonnei 53G, Shigella flexneri 2a 2457T
- Biological
- Lead sponsor
- PATH
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Cerebral Palsy
- Interventions
- Short Burst Interval Treadmill Training (SBLTT), Traditional Locomotor Treadmill Training (TLTT)
- Behavioral
- Lead sponsor
- Kristie Bjornson
- Other
- Eligibility
- 6 Years to 10 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 2
- States / cities
- New Orleans, Louisiana • Seattle, Washington
- Conditions
- Nicotine Addiction
- Interventions
- 2-[18F]-fluro-3-[2(S)-2-azethidinylmethoxy]-pyridine
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Gastroesophageal Reflux
- Interventions
- rabeprazole sodium
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Bulimia Nervosa
- Interventions
- Fasting state, Fed state, Magnetic Resonance Imaging
- Other
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Danirixin HBr 50 mg IR Tablet, Danirixin FB 50 mg IR Tablet, Prilosec (omeprazole) 40mg Delayed-Release capsule
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 65 Years to 80 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Epilepsy
- Interventions
- Lamotrigine tablet, Lamotrigine caplet
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 209 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Tacoma, Washington
- Conditions
- Healthy
- Interventions
- Miricorilant Treatment A, Miricorilant Treatment B, Miricorilant Treatment C, Miricorilant Treatment D
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Healthy
- Interventions
- Seltorexant 40 mg, Seltorexant 20 mg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Healthy
- Interventions
- PF-04634817 Placebo, PF-04634817
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Inflammatory Disease
- Interventions
- Lanraplenib.
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 3
- States / cities
- Miami, Florida • Orlando, Florida
- Conditions
- Carbohydrate Metabolism
- Interventions
- CS- Beverage, CS+Fast, CS+Slow
- Other
- Lead sponsor
- Virginia Polytechnic Institute and State University
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Roanoke, Virginia
- Conditions
- Solid Tumor, Adult
- Interventions
- ASTX029
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 19
- States / cities
- Duarte, California • Los Angeles, California • Newport Beach, California + 13 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- PF-05161704 or placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- CAB, RIF
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Healthy Volunteers in Fed and Fasted State
- Interventions
- Dexmethylphenidate
- Drug
- Lead sponsor
- Cingulate Therapeutics
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Healthy Volunteer Study
- Interventions
- Glasdegib Oral Tablet, Glasdegib IV infusion
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Healthy Participants
- Interventions
- Etrumadenant
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Drug Interaction Study
- Interventions
- Pacritinib, Clarithromycin, Pacritinib and Clarithromycin
- Drug
- Lead sponsor
- CTI BioPharma
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- GSK2586184 standard formulation, Simvastatin, Rosuvastatin, GSK2586184 new formulation
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland